Prosight Management’s Sio Gene Therapies SIOX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-670,300
Closed -$449K – 38
2022
Q1
$449K Sell
670,300
-131,880
-16% -$112K 0.29% 30
2021
Q4
$1.04M Buy
802,180
+308,972
+63% +$548K 0.62% 29
2021
Q3
$1.07M Buy
493,208
+237,093
+93% +$516K 0.59% 36
2021
Q2
$699K Buy
256,115
+50,215
+24% +$125K 0.44% 37
2021
Q1
$537K Buy
+205,900
New +$582K 0.44% 32

Other funds holding SIOX

Prosight Management's SIOX Position: Q2 2022 in Review

Prosight Management sold out of Sio Gene Therapies (SIOX) in Q2 2022, closing a stake of 670,300 shares — an estimated $449K sold.

Prosight Management first reported a position in SIOX in Q1 2021 and held it in 5 quarters. The position peaked at $1.07M in Q3 2021. 41 funds tracked by Wall St. Rank hold SIOX as of Q2 2022.

  • Prosight Management reported no remaining Sio Gene Therapies position as of Q2 2022 after selling out during the quarter.
  • Prosight Management sold 670,300 Sio Gene Therapies shares in Q2 2022, an estimated $449K.
  • Prosight Management first reported a position in Sio Gene Therapies in Q1 2021 and held it in 5 quarters.
  • Prosight Management's Sio Gene Therapies position peaked at $1.07M in Q3 2021.
  • 41 funds tracked by Wall St. Rank held Sio Gene Therapies as of Q2 2022.

Based on Prosight Management's 13F filing for Q2 2022, filed 12 Aug 2022.